We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Wall Street losses accelerated on Friday, with investors closing out the week with gloomy economic updates and report of a government investigation into UnitedHealth (UNH) in hand. However, the S&P ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

The FDA granted orphan designation to Sanofi ( SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on TheFly – ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).